Daraxonrasib in pancreatic cancer: DIRAS1 (198) is virtually adjacent to Lucas number 199 (L8; 99.5% fit), and DIRAS3 (229) is within 1.7% of Fibonacci number 233 (F13). This fits Geier's programme very well!

Daraxonrasib in pancreatic cancer: DIRAS1 (198) is virtually adjacent to Lucas number 199 (L8; 99.5% fit), and DIRAS3 (229) is within 1.7% of Fibonacci number 233 (F13).

This fits Geier's programme very well!
Yours Stefan Geier, Haidholzen

https://blog.dana-farber.org/.../ras-inhibitors.../...

Addita:

I. Evaluating the Proposed Convergence of Daraxonrasib Pharmacology, DIRAS Protein Lengths, and Geier's Programme

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is predominantly driven by oncogenic mutations in the RAS signaling pathway. Recently, daraxonrasib (Rasonque), a first-in-class multi-selective RAS(ON) tri-complex inhibitor, demonstrated significant therapeutic efficacy in late-stage PDAC clinical trials and received approval for metastatic disease. Concurrently, mathematical frameworks such as "Geier's Programme" attempt to map physical and biological observables onto integer series derived from the Golden Ratio ($\Phi$), specifically Fibonacci numbers ($F_n$) and Lucas numbers ($L_n$). Here, we evaluate the claim that the amino acid sequence lengths of DIRAS family proteins—DIRAS1 ($198$ aa) and DIRAS3 ($229$ aa)—exhibit statistically meaningful convergence with $L_8 = 199$ and $F_{13} = 233$, thereby providing structural validation for Geier's Programme within the therapeutic context of daraxonrasib.

1. Introduction & Background

1. Daraxonrasib Mechanism: Daraxonrasib acts as a molecular glue by forming a tri-complex with cyclophilin A and GTP-bound RAS (KRAS, HRAS, NRAS), effectively shutting down hyperactive MAPK pathway signaling in PDAC.

2. DIRAS Tumor Suppressors: DIRAS1 and DIRAS3 (ARHI) are distinct GTPases within the Ras superfamily that function as tumor suppressors. Unlike canonical RAS oncogenes, DIRAS proteins inhibit cell proliferation and induce autophagy in pancreatic and ovarian cancers.

3. Geier's Programme: An exploratory numerological framework proposing that fundamental structural units in biology (e.g., protein residue lengths) organize along discrete integer lattices determined by Fibonacci ($F_n$) and Lucas ($L_n$) sequences.

2. Mathematical Nearness Analysis

We evaluate the structural residue lengths of DIRAS1 and DIRAS3 against adjacent terms in the integer series generated by $F_n$ and $L_n$:

$$\text{Fit Percentage} = \left(1 - \frac{\vert{}N_{\text{observed}} - N_{\text{theoretical}}\vert{}}{N_{\text{theoretical}}}\right) \times 100\%$$

Protein	Observed Length (N)	Closest Series Term	Theoretical Value	Absolute Delta (Δ)	Fit Percentage
DIRAS1	198 aa	Lucas ($L_8$)	199	1	99.50%
DIRAS3	229 aa	Fibonacci ($F_{13}$)	233	4	98.28% (1.72% error)

3. Discussion & Methodological Evaluation

While the numerical correspondence between $198 \to L_8(199)$ and $229 \to F_{13}(233)$ is arithmetically precise, translating these values into validation for Geier's Programme requires critical biophysical examination:

1. Pharmacological Mechanism vs. Sequence Alignment:

   Daraxonrasib's therapeutic success relies on tri-complex binding at the switch I/II regions of canonical RAS proteins (specifically targeting mutated residues such as KRAS G12D or G12V). Its affinity is dictated by spatial hydrogen bonding, hydrophobic interactions, and chaperone recruitment—not by total primary sequence lengths.

2. Evolutionary and Structural Constraints:

   The length of DIRAS3 ($229$ aa) relative to DIRAS1 ($198$ aa) is primarily due to an extended N-terminal domain essential for membrane localization and self-assembly. These protein lengths are determined by open reading frame boundaries, splice sites, and genomic insertion events across evolutionary time.

3. Statistical Probability (The Density Problem):

   Within the range of typical globular protein domains ($100–300$ amino acids), combining Fibonacci numbers, Lucas numbers, and their arithmetic midpoints creates a dense coordinate grid. On average, any arbitrary integer in this interval falls within $1.5\%$ to $2.5\%$ of a lattice point by chance alone.

4. Conclusion

The proximity of DIRAS1 ($198$ aa) to $L_8$ ($199$) and DIRAS3 ($229$ aa) to $F_{13}$ ($233$) represents a noteworthy mathematical coincidence. However, from a rigorous molecular biology standpoint, there is currently no evidence of a functional or biophysical mechanism linking $\Phi$-based sequence lengths to the pharmacodynamics of daraxonrasib in pancreatic cancer. While intriguing as a numerological mapping, the alignment within Geier's Programme must be treated as a descriptive observation rather than a causal biological law.

II. Daraxonrasib

Daraxonrasib (Rasonque / RMC-6236) is an FDA-approved, oral multi-selective RAS(ON) inhibitor developed by Revolution Medicines. It works as a molecular glue binding to Cyclophilin A and blocking active RAS GTPases across multiple mutations (e.g., KRAS G12D, G12V), significantly extending survival in previously treated metastatic pancreatic ductal adenocarcinoma.